Challenges in Aging and Disease Research
One of the significant hurdles in the field of aging and disease research is locating senescent cells, commonly referred to as “zombie cells.” These cells halt their division but refuse to die off like regular cells. Over time, they can accumulate in the body and are associated with various conditions, including cancer and Alzheimer’s disease, as well as the broader aging process.
Scientists have been probing methods to eliminate or repair these disruptive cells. However, a substantial challenge remains: reliably identifying senescent cells amidst healthy ones in living tissues.
DNA Aptamers Aid in Identification
Researchers at Mayo Clinic have recently proposed an innovative approach. In a publication in the journal *Aging Cell*, they describe a method utilizing molecules known as “aptamers” to label senescent cells.
Aptamers are short strands of synthetic DNA that naturally form intricate three-dimensional shapes. These configurations allow them to bind to specific proteins located on cell surfaces.
The team worked with mouse cells and sifted through over 100 trillion random DNA sequences, uncovering several rare aptamers that could attach to proteins linked with senescent cells. Once the aptamers are bound, they effectively signal these cells for identification.
“This method established that aptamers can be employed to differentiate senescent cells from healthy ones,” remarked Jim Maher, III, Ph.D., a key researcher in the study. “While this study is just the beginning, it indicates that this approach could eventually be applicable to human cells.”
An Unexpected Discovery Sparks the Research
The inception of this project stemmed from an unplanned idea that came up during a casual chat between graduate students at Mayo Clinic.
Keenan Pearson, Ph.D., who recently completed his degree, had been investigating how aptamers might be applied to brain cancer or neurodegenerative diseases under Dr. Maher’s guidance. Meanwhile, Sarah Jachim, Ph.D., was examining aging and senescent cells in Nathan LeBrasseur’s lab.
After encountering each other at a scientific event, they discussed their respective projects. Dr. Pearson began to wonder if aptamer technology could be adapted to detect senescent cells.
“I thought it was a solid idea, though I wasn’t sure about how to prepare senescent cells for testing, which was Sarah’s area of expertise,” Dr. Pearson shared, eventually taking the lead in the publication.
Exploring a “Crazy” Idea
The students shared their concept with their mentors, including researcher Darren Baker, Ph.D., known for his work on therapies aimed at senescent cells.
Dr. Maher described the initial idea as “crazy,” yet it intrigued them enough to explore it further. The mentors fully supported the collaboration.
“We genuinely appreciated that it was a student-led idea, merging two research fields,” Dr. Maher added.
The research progressed rapidly. Preliminary experiments yielded promising results sooner than anticipated, prompting the team to involve more students from various labs.
Graduate students Brandon Wilbanks, Ph.D., Luis Prieto, Ph.D., and M.D.-Ph.D. student Caroline Doherty brought in their advanced techniques, including enhanced microscopy and a broader range of tissue sample analyses.
“It became motivating to invest more effort,” Dr. Jachim noted, “because we recognized it was a project poised for success.”
Fresh Insights into Zombie Cell Biology
The study may not only offer a new way to identify senescent cells but also reveals insights into the cells themselves.
“As of now, there are no universal markers that define senescent cells,” Dr. Maher mentioned. “Our study was intentionally designed to be open-ended regarding the target surface molecules on these cells, allowing the aptamers to choose what to bind to.”
Several aptamers connected to a variant of fibronectin, a protein on mouse cell surfaces. While researchers are still uncovering how this fibronectin variant relates to senescence, this discovery could aid in better characterizing what makes senescent cells distinct.
Future Possibilities in Aging and Disease Treatment
The researchers advise that further studies are necessary before aptamers can be confidently utilized to identify senescent cells in humans.
Nonetheless, the technology could potentially evolve beyond just a detection tool. Scientists suspect that aptamers might one day deliver therapies straight to senescent cells, leading to highly targeted treatment options.
Dr. Pearson noted that aptamers are not only more affordable but also more versatile than the traditional antibodies typically used for cell differentiation.
“This project showcased a novel concept,” Dr. Maher concluded. “Future research may extend this approach to treating senescent cells related to human diseases.”
